vs
EXACT SCIENCES CORP（EXAS）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是RadNet, Inc.的1.6倍（$878.4M vs $547.7M）。RadNet, Inc.净利率更高（-0.1% vs -9.8%，领先9.7%）。EXACT SCIENCES CORP同比增速更快（23.1% vs 14.8%）。过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 12.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
EXAS vs RDNT — 直观对比
营收规模更大
EXAS
是对方的1.6倍
$547.7M
营收增速更快
EXAS
高出8.3%
14.8%
净利率更高
RDNT
高出9.7%
-9.8%
两年增速更快
EXAS
近两年复合增速
12.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $547.7M |
| 净利润 | $-86.0M | $-597.0K |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 5.1% |
| 净利率 | -9.8% | -0.1% |
| 营收同比 | 23.1% | 14.8% |
| 净利润同比 | 90.1% | -111.2% |
| 每股收益（稀释后） | $-0.45 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRDNT
| Q4 25 | $878.4M | $547.7M | ||
| Q3 25 | $850.7M | $522.9M | ||
| Q2 25 | $811.1M | $498.2M | ||
| Q1 25 | $706.8M | $471.4M | ||
| Q4 24 | $713.4M | $477.1M | ||
| Q3 24 | $708.7M | $461.1M | ||
| Q2 24 | $699.3M | $459.7M | ||
| Q1 24 | $637.5M | $431.7M |
净利润EXASRDNT
| Q4 25 | $-86.0M | $-597.0K | ||
| Q3 25 | $-19.6M | $5.4M | ||
| Q2 25 | $-1.2M | $14.5M | ||
| Q1 25 | $-101.2M | $-37.9M | ||
| Q4 24 | $-864.6M | $5.3M | ||
| Q3 24 | $-38.2M | $3.2M | ||
| Q2 24 | $-15.8M | $-3.0M | ||
| Q1 24 | $-110.2M | $-2.8M |
毛利率EXASRDNT
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASRDNT
| Q4 25 | -9.4% | 5.1% | ||
| Q3 25 | -3.0% | 5.2% | ||
| Q2 25 | -0.3% | 6.2% | ||
| Q1 25 | -13.6% | -5.1% | ||
| Q4 24 | -122.8% | 5.1% | ||
| Q3 24 | -5.6% | 7.4% | ||
| Q2 24 | -3.8% | 7.6% | ||
| Q1 24 | -16.7% | 2.6% |
净利率EXASRDNT
| Q4 25 | -9.8% | -0.1% | ||
| Q3 25 | -2.3% | 1.0% | ||
| Q2 25 | -0.1% | 2.9% | ||
| Q1 25 | -14.3% | -8.0% | ||
| Q4 24 | -121.2% | 1.1% | ||
| Q3 24 | -5.4% | 0.7% | ||
| Q2 24 | -2.3% | -0.6% | ||
| Q1 24 | -17.3% | -0.6% |
每股收益（稀释后）EXASRDNT
| Q4 25 | $-0.45 | $0.00 | ||
| Q3 25 | $-0.10 | $0.07 | ||
| Q2 25 | $-0.01 | $0.19 | ||
| Q1 25 | $-0.54 | $-0.51 | ||
| Q4 24 | $-4.69 | $0.08 | ||
| Q3 24 | $-0.21 | $0.04 | ||
| Q2 24 | $-0.09 | $-0.04 | ||
| Q1 24 | $-0.60 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $767.2M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $2.4B | $1.1B |
| 总资产 | $5.9B | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资EXASRDNT
| Q4 25 | $964.7M | $767.2M | ||
| Q3 25 | $1.0B | $804.7M | ||
| Q2 25 | $858.4M | $833.2M | ||
| Q1 25 | $786.2M | $717.3M | ||
| Q4 24 | $1.0B | $740.0M | ||
| Q3 24 | $1.0B | $748.9M | ||
| Q2 24 | $946.8M | $741.7M | ||
| Q1 24 | $652.1M | $527.0M |
总债务EXASRDNT
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $834.6M |
股东权益EXASRDNT
| Q4 25 | $2.4B | $1.1B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.5B | $932.3M | ||
| Q1 25 | $2.4B | $898.1M | ||
| Q4 24 | $2.4B | $902.3M | ||
| Q3 24 | $3.2B | $895.3M | ||
| Q2 24 | $3.2B | $881.0M | ||
| Q1 24 | $3.1B | $873.0M |
总资产EXASRDNT
| Q4 25 | $5.9B | $3.8B | ||
| Q3 25 | $5.9B | $3.7B | ||
| Q2 25 | $5.8B | $3.5B | ||
| Q1 25 | $5.7B | $3.3B | ||
| Q4 24 | $5.9B | $3.3B | ||
| Q3 24 | $6.7B | $3.3B | ||
| Q2 24 | $6.7B | $3.2B | ||
| Q1 24 | $6.4B | $3.0B |
负债/权益比EXASRDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRDNT
| Q4 25 | $151.7M | $84.2M | ||
| Q3 25 | $219.9M | $52.8M | ||
| Q2 25 | $89.0M | $120.3M | ||
| Q1 25 | $30.8M | $41.5M | ||
| Q4 24 | $47.1M | $42.5M | ||
| Q3 24 | $138.7M | $57.4M | ||
| Q2 24 | $107.1M | $116.0M | ||
| Q1 24 | $-82.3M | $17.1M |
自由现金流EXASRDNT
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASRDNT
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASRDNT
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASRDNT
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
